Anti-Ro_JJ
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
autoantibodies_NNS
are_VBP
associated_VBN
with_IN
T_NN
cell_NN
receptor_NN
beta_NN
genes_NNS
in_IN
systemic_JJ
lupus_NN
erythematosus_NN
patients_NNS
._.

Several_JJ
of_IN
the_DT
heterogeneous_JJ
clinical_JJ
manifestations_NNS
of_IN
systemic_JJ
lupus_NN
erythematosus_NN
have_VBP
been_VBN
associated_VBN
with_IN
specific_JJ
autoantibodies_NNS
._.

Associations_NNS
between_IN
HLA_NN
class_NN
II_CD
antigens_NNS
and_CC
autoantibodies_NNS
to_TO
the_DT
ribonucleoproteins_JJ
Ro_NN
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
and_CC
La_NN
-LRB-_-LRB-
SSB_NN
-RRB-_-RRB-
have_VBP
been_VBN
reported_VBN
in_IN
these_DT
patients_NNS
._.

Because_IN
HLA_NN
class_NN
II_CD
molecules_NNS
present_VBP
antigen_NN
to_TO
T_NN
cell_NN
receptors_NNS
-LRB-_-LRB-
TCRs_NNS
-RRB-_-RRB-
,_,
we_PRP
have_VBP
searched_VBN
for_IN
a_DT
TCR_NN
gene_NN
associated_VBN
with_IN
the_DT
production_NN
of_IN
anti-Ro_NN
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
antibodies_NNS
._.

A_DT
pair_NN
of_IN
restriction_NN
fragment_NN
length_NN
polymorphisms_NNS
-LRB-_-LRB-
RFLPs_NNS
-RRB-_-RRB-
,_,
one_CD
of_IN
which_WDT
hybridizes_VBZ
to_TO
the_DT
TCR_NN
constant_NN
region_NN
C_NN
beta_NN
1_CD
and_CC
the_DT
other_JJ
to_TO
the_DT
C_NN
beta_NN
2_CD
gene_NN
,_,
has_VBZ
been_VBN
identified_VBN
,_,
suggesting_VBG
these_DT
may_MD
be_VB
genotypic_JJ
markers_NNS
for_IN
an_DT
extended_VBN
region_NN
of_IN
the_DT
TCR_NN
beta_NN
locus_NN
._.

This_DT
RFLP_NN
pair_NN
occurs_VBZ
in_IN
76_CD
%_NN
of_IN
patients_NNS
with_IN
Ro_NN
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
precipitins_NNS
,_,
84_CD
%_NN
of_IN
anti-Ro_NN
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
-_:
positive_JJ
patients_NNS
lacking_VBG
La_NN
-LRB-_-LRB-
SSB_NN
-RRB-_-RRB-
precipitins_NNS
,_,
but_CC
only_RB
41_CD
%_NN
of_IN
the_DT
patients_NNS
lacking_VBG
both_DT
precipitins_NNS
-LRB-_-LRB-
P_NN
=_JJ
0.0004_CD
-RRB-_-RRB-
._.

This_DT
disproportionate_JJ
occurrence_NN
in_IN
a_DT
subset_NN
of_IN
lupus_NN
patients_NNS
indicates_VBZ
that_IN
these_DT
RFLPs_NNS
are_VBP
not_RB
disease_NN
susceptibility_NN
markers_NNS
,_,
but_CC
rather_RB
are_VBP
important_JJ
markers_NNS
for_IN
TCR_NN
genes_NNS
whose_WP$
products_NNS
are_VBP
involved_VBN
in_IN
the_DT
production_NN
of_IN
anti-Ro_NN
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
antibodies_NNS
._.

The_DT
majority_NN
of_IN
patients_NNS
who_WP
have_VBP
these_DT
RFLPs_NNS
and_CC
HLA_NN
class_NN
II_CD
antigens_NNS
previously_RB
associated_VBN
with_IN
the_DT
anti-Ro_NN
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
response_NN
make_VBP
this_DT
antibody_NN
,_,
suggesting_VBG
that_IN
interactions_NNS
between_IN
products_NNS
of_IN
these_DT
loci_NNS
occur_VBP
in_IN
response_NN
to_TO
Ro_NN
-LRB-_-LRB-
SSA_NN
-RRB-_-RRB-
._.

